Colorado Medicaid spending on GLP-1 drugs

How much did Colorado Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $127.2 million for GLP-1 drugs paid through Colorado Medicaid in 2025, across at least 123,012 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 69 rows of 284, so these figures are floors.

Pharmacies were reimbursed at least $40.3 million for GLP-1 drugs paid through Colorado Medicaid in 2026 (quarter 1 only, as posted so far), across at least 38,302 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 25 rows of 81, so these figures are floors.

By year and ingredient

2020at least $672,839No data$6,347,020at least $1,800,712at least $8,593,819No dataSuppressedat least $10,348at least $17,424,738
2021at least $1,328,024No data$9,268,520at least $16,157,608at least $3,800,328SuppressedSuppressedat least $9,341at least $30,563,821
2022at least $2,996,038at least $280,996$8,271,036at least $39,523,307at least $993,555SuppressedSuppressedat least $13,446at least $52,078,377
2023at least $7,564,301at least $5,482,709at least $9,257,283at least $59,751,795at least $727,911No dataSuppressedSuppressedat least $82,783,999
2024at least $13,781,045at least $13,384,150at least $5,628,029at least $54,578,697at least $694,357No dataSuppressedSuppressedat least $88,066,278
2025at least $28,496,961at least $33,126,995at least $2,568,914at least $62,739,106at least $259,650No dataat least $7,471Suppressedat least $127,199,098
2026 (Q1)at least $14,052,459at least $12,983,188at least $474,469$12,834,759SuppressedNo dataSuppressedSuppressedat least $40,344,875

By product, 2025

Ozempic$19,310,18119,1130 of 24
Rybelsusat least $1,012,981at least 8523 of 24
Wegovyat least $8,173,798at least 6,80614 of 39
Mounjaro$26,350,38724,5860 of 48
Zepboundat least $6,776,608at least 7,44313 of 40
Liraglutide (generic name listing)at least $1,745,818at least 4,23319 of 45
SaxendaSuppressedSuppressed4 of 4
Victozaat least $823,096at least 1,8262 of 10
Trulicityat least $62,739,106at least 57,8941 of 32
Bydureonat least $164,885at least 1581 of 3
Byettaat least $94,766at least 903 of 5
Exenatide (generic name listing)SuppressedSuppressed3 of 3
Soliquaat least $7,471at least 112 of 3
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $27,964,649at least 23,83015 of 64
Q2 2025at least $31,650,865at least 31,10218 of 73
Q3 2025at least $32,590,294at least 32,83519 of 75
Q4 2025at least $34,993,290at least 35,24517 of 72

By quarter, 2026 (posted so far)

Q1 2026at least $40,344,875at least 38,30225 of 81

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.